Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
0.73 (USD) • At close January 15, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Lexicon Pharmaceuticals, Inc. |
Symbool | LXRX |
Munteenheid | USD |
Prijs | 0.728 |
Beurswaarde | 263,021,579 |
Dividendpercentage | 0% |
52-weken bereik | 0.62 - 3.73 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Lonnel Coats |
Website | https://www.lexpharma.com |
An error occurred while fetching data.
Over Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)